Monday, Feb. 24 Tuesday, Feb. 25 Wednesday, Feb. 26

sunday, february 23

• Educational Sessions 1-2       
  • Detection of Tumor-Reactive T Cells
  • Strategies to Overcome Manufacturing Challenges for Cell-based Therapy                                                                                                      
• Educational Sessions 3-4
  • Spatial Organization of Immune Cells and Treatment with Immunotherapy
  • T-Cell Therapies: Advances and Challenges
• Welcome and Keynote Session 1

*-Short talk from proffered abstract

registration

12-9 p.m. | Diamond Foyer

EDUCATIONAL SESSIONS 1 AND 2

3:30-4:50 p.m.

educational session 1: detection of tumor-reactive t cells

Diamond Ballroom 4-5

Session Chair: Stephen Schoenberger, La Jolla Institute for Immunology, La Jolla, California

• 3:35 p.m. | Deciphering the properties of anti-tumor T cells in solid cancers
  Giacomo Oliveira, Harvard Medical School, Cambridge, Massachusetts
• 3:55 p.m. | Longitudinal landscape analysis of the neoantigen-specific T-cell responses in patients with melanoma with or without response to PD1 blockade
  Cristina Puig Saus, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California
• 4:15 p.m. | Rapid and efficient isolation of neoantigen-specific TCRs from PBMC in low TMB tumor patients
  Stephen Schoenberger
• 4:35 p.m. | Discussion / Q&A

EDUCATIONAL SESSION 2: Strategies to Overcome Manufacturing Challenges for Cell-Based Therapy

Diamond Ballroom 1-3

Session Chair: Marc Better, Pharmefex, Bellevue, Washington

• 3:35 p.m. | Navigating production success: Key considerations for T cell-based therapies
  Michal Besser, Rabin Medical Center, Petach Tilva, Israel
• 3:50 p.m. | Evolving CAR T cell therapies: from autologous to allogeneic
  Isabelle Rivière, Takeda, Cambridge, Massachusetts
• 4:05 p.m. | Developing and manufacturing next generation cell therapies in the academic setting
  Brian Shy, University of California, San Francisco, California
• 4:15 p.m. | The coming patient treatment crisis
  Arturo Araya, Cellares, San Francisco, California
• 4:35 p.m. | Discussion / Q&A

break

4:50-5:20 p.m. | Diamond Foyer

EDUCATIONAL SESSIONS 3 AND 4

5:20-6:40 p.m.

EDUCATIONAL SESSION 3: Spatial Organization of Immune Cells and Treatment with Immunotherapy

Diamond Ballroom 4-5

Session Chair: Nir Hacohen, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts

• 5:25 p.m. | Spatial organization of immune cells in tumors
  Nir Hacohen
• 5:42 p.m. | Not all T cell responses are equal: bringing context into the cancer immunity cycle
  Stefani Spranger, Koch Institute for Integrative Cancer Research at MIT, Boston, Massachusetts
• 5:59 p.m. | Intratumoral B cells are essential for anti-tumor immune responses of tertiary lymphoid structures: Impact of STING and LTβR activation in pancreatic cancer*
  Maxwell Duah, Johns Hopkins All Children’s Hospital, St. Petersburg, Florida
• 6:09 p.m. | T cell engager therapy affects the spatial distribution and phenotype of T cells in the tumor microenvironment*
  William H. Tomaszewski, Genentech, South San Francisco, California
• 6:19 p.m. | The development of distinct immune suppressive mechanisms facilitates the transition of human lung cancer from preinvasive lesions to invasive disease*
  Liron Yoffe, Weill Cornell Medicine, New York, New York
• 6:29 p.m. | Discussion / Q&A

EDUCATIONAL SESSION 4: T-cell Therapies: Advances and Challenges

Diamond Ballroom 1-3

Session Chair: Yvonne Y. Chen, University of California, Los Angeles, California

• 5:25 p.m. | CRISPR engineering of T cells
  Julia Carnevale, University of California, San Francisco, California
• 5:45 p.m. | Multi-pronged CAR-T cell therapy for cancer
  Yvonne Y. Chen
• 6:05 p.m.
  Aude G. Chapuis, Fred Hutchinson Cancer Center, Seattle, Washington
• 6:25 p.m. | Discussion / Q&A

WELCOME AND keynote SESSION 1

Diamond Ballroom 4-5

6:50-8 p.m.

• 7:05 p.m. | Celebrating 30 years of CTLA-4
  James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas
• 7:35 p.m. | The biology behind PD-1 checkpoint blockade
  Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts

Opening reception

8-10 p.m. | Diamond Ballroom 6-10